Poor evidence is used to support commercial payers' coverage policies for shoulder arthroplasty
Copyright © 2023 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved..
BACKGROUND: The incidence of shoulder arthroplasty has continued to increase over the past decade. In response, commercial payers have implemented strategies to control the medical requirement of these surgeries in attempt to contain the growing costs. For example, most payers require a prolonged trial of conservative management prior to shoulder arthroplasty for patients who may otherwise be surgical candidates. However, little is known regarding the evidence used to support these indications. The purpose of this study was to analyze the references used by commercial payers to substantiate their coverage policies for shoulder arthroplasty.
METHODS: Ten of the leading commercial payers for total shoulder arthroplasty were identified. Publicly available coverage policies were searched on the internet or requested directly from the payer via email or telephone. Cited references were reviewed independently by two authors for type of document, level of evidence, and mention of the efficacy of conservative management.
RESULTS: A total of 5 coverage policies were obtained with 118 references. The most common reference type was primary journal article (n = 70; 59.3%) followed by review or expert opinion articles (n = 35; 29.7%). Most references were of level IV evidence (n = 60; 52.2%), with only 6 (5.2%) of level I or II evidence. Only 4 (3.5%) references mentioned the efficacy of conservative management in patients who may be candidates for shoulder arthroplasty.
CONCLUSION: The majority of references used to substantiate the coverage policies for shoulder arthroplasty among major commercial payers within the United States are of low scientific evidence and fail to demonstrate the success of required nonoperative intervention strategies. Our study underscores the need for high-quality, comparative trials that evaluate the outcomes of conservative management vs. shoulder arthroplasty in end-stage glenohumeral osteoarthritis patients in order to determine the most cost-effective treatment algorithm.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Journal of shoulder and elbow surgery - 32(2023), 11 vom: 10. Nov., Seite 2222-2231 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sudah, Suleiman Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Commercial payers |
|---|
| Anmerkungen: |
Date Revised 15.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jse.2023.04.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357499565 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357499565 | ||
| 003 | DE-627 | ||
| 005 | 20231226072727.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jse.2023.04.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357499565 | ||
| 035 | |a (NLM)37247779 | ||
| 035 | |a (PII)S1058-2746(23)00391-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sudah, Suleiman Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Poor evidence is used to support commercial payers' coverage policies for shoulder arthroplasty |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Journal of Shoulder and Elbow Surgery Board of Trustees. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The incidence of shoulder arthroplasty has continued to increase over the past decade. In response, commercial payers have implemented strategies to control the medical requirement of these surgeries in attempt to contain the growing costs. For example, most payers require a prolonged trial of conservative management prior to shoulder arthroplasty for patients who may otherwise be surgical candidates. However, little is known regarding the evidence used to support these indications. The purpose of this study was to analyze the references used by commercial payers to substantiate their coverage policies for shoulder arthroplasty | ||
| 520 | |a METHODS: Ten of the leading commercial payers for total shoulder arthroplasty were identified. Publicly available coverage policies were searched on the internet or requested directly from the payer via email or telephone. Cited references were reviewed independently by two authors for type of document, level of evidence, and mention of the efficacy of conservative management | ||
| 520 | |a RESULTS: A total of 5 coverage policies were obtained with 118 references. The most common reference type was primary journal article (n = 70; 59.3%) followed by review or expert opinion articles (n = 35; 29.7%). Most references were of level IV evidence (n = 60; 52.2%), with only 6 (5.2%) of level I or II evidence. Only 4 (3.5%) references mentioned the efficacy of conservative management in patients who may be candidates for shoulder arthroplasty | ||
| 520 | |a CONCLUSION: The majority of references used to substantiate the coverage policies for shoulder arthroplasty among major commercial payers within the United States are of low scientific evidence and fail to demonstrate the success of required nonoperative intervention strategies. Our study underscores the need for high-quality, comparative trials that evaluate the outcomes of conservative management vs. shoulder arthroplasty in end-stage glenohumeral osteoarthritis patients in order to determine the most cost-effective treatment algorithm | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Level of evidence | |
| 650 | 4 | |a commercial payers | |
| 650 | 4 | |a glenohumeral osteoarthritis | |
| 650 | 4 | |a heath care policy | |
| 650 | 4 | |a shoulder arthroplasty | |
| 650 | 4 | |a treatment algorithm | |
| 700 | 1 | |a Faccone, Robert D |e verfasserin |4 aut | |
| 700 | 1 | |a Imam, Nareena |e verfasserin |4 aut | |
| 700 | 1 | |a Patankar, Aneesh |e verfasserin |4 aut | |
| 700 | 1 | |a Manzi, Joseph E |e verfasserin |4 aut | |
| 700 | 1 | |a Menendez, Mariano E |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholson, Allen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of shoulder and elbow surgery |d 1992 |g 32(2023), 11 vom: 10. Nov., Seite 2222-2231 |w (DE-627)NLM07528877X |x 1532-6500 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:11 |g day:10 |g month:11 |g pages:2222-2231 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jse.2023.04.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 11 |b 10 |c 11 |h 2222-2231 | ||